Bio tech company updates — 7/22/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biotech companies are making significant strategic moves this week: Y-Biologics plans to launch global technology transfer talks after presenting November data, Seoul partners with Samsung Bioepis to nurture biotech startups, and Samsung Biologics pursues its largest-ever acquisition of Swiss peptide manufacturer PolyPeptide for $1.8 billion.
Key Findings
Seoul-Samsung Bioepis Partnership Launched — Seoul city government is partnering with Samsung Bioepis to identify and develop biotechnology startups focused on next-generation drug technologies, marking a collaborative effort to strengthen Korea's biotech innovation pipeline.
Y-Biologics CEO Targets Global Tech Transfer — Y-Biologics CEO Park Beom-chan plans to present core pipeline data for its Multi-AbCine triple antibody platform at the Society for Immunotherapy of Cancer (SITC) conference in November to advance international technology transfer discussions. The company uses translational research that verifies drug efficacy with patient cancer tissue, bridging the gap between animal preclinical studies and human clinical trials, currently focusing on lung cancer and colorectal cancer applications.
Samsung Biologics Pursues Landmark Peptide Acquisition — Samsung Biologics announced an all-cash bid to acquire 100 percent of Switzerland's PolyPeptide Group for approximately $1.8 billion (2.7 trillion won), representing the largest M&A deal in Korean pharmaceutical and biotechnology history. The acquisition will expand Samsung's manufacturing capabilities in peptide drugs and strengthen its position in the obesity drug market.
Details
The Seoul-Samsung Bioepis initiative represents a strategic move to accelerate biotech startup development at a time when Korean biotech companies are increasingly competitive globally. Samsung Bioepis will leverage its expertise to mentor emerging companies developing next-generation therapeutic approaches.
Y-Biologics' strategy highlights the company's confidence in its Multi-AbCine platform, which combines multiple antibodies in a single therapeutic agent. By presenting comprehensive clinical data at SITC in November, the company aims to attract global pharmaceutical and biotech partners for licensing or collaboration agreements, following a translational research validation phase that demonstrates real-world efficacy.
Samsung Biologics' acquisition of PolyPeptide marks a major consolidation move in the peptide manufacturing sector. The deal positions Samsung to capture growing demand in obesity treatment markets while expanding its contract development and manufacturing organization (CDMO) capabilities beyond monoclonal antibodies into peptide therapeutics—a complementary but distinct technology domain.
Sources
Korean Biotechs Race to Develop Next-Generation ADCs - Seoul Economic Daily
Samsung Biologics Shares Slip Early After 2.7 Trillion Won Acquisition - Seoul Economic Daily
Y-Biologics CEO Aims to Launch Tech Transfer After November Data Release - Seoul Economic Daily
koreajoongangdaily.com
koreatimes.co.kr
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
